Cargando…

PNP inhibitors selectively kill cancer cells lacking SAMHD1

Purine nucleoside phosphorylase inhibitors (PNP-Is) were developed to ablate transformed lymphocytes. However, only some patients with leukemia benefit from PNP-Is. We provide a molecular explanation: the deoxyribonucleoside triphosphate (dNTP) hydrolase SAM and HD domain-containing protein 1 (SAMHD...

Descripción completa

Detalles Bibliográficos
Autores principales:	Davenne, Tamara, Rehwinkel, Jan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2020
Materias:	Author’s Views
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7671039/ https://www.ncbi.nlm.nih.gov/pubmed/33235905 http://dx.doi.org/10.1080/23723556.2020.1804308

Ejemplares similares

SAMHD1 is a barrier to antimetabolite-based cancer therapies
por: Rudd, Sean G., et al.
Publicado: (2017)

Killing from within
por: Mumm, John B., et al.
Publicado: (2012)

Inducing DNA damage through R-loops to kill cancer cells
por: Lam, Fred C., et al.
Publicado: (2020)

SAMHD1 protects cancer cells from various nucleoside-based antimetabolites
por: Herold, Nikolas, et al.
Publicado: (2017)

How imiquimod licenses plasmacytoid dendritic cells to kill tumors
por: Holcmann, Martin, et al.
Publicado: (2012)

Sp3-cificity of TNF-α expression promotes the Smac mimetic-mediated killing of cancer cells
por: Beug, Shawn T., et al.
Publicado: (2019)

CDK1/2/5 blockade: killing two birds with one stone
por: Liu, Jiao, et al.
Publicado: (2021)

License to kill: microsatellite instability and immune contexture
por: Maby, Pauline, et al.
Publicado: (2021)

Anticancer Tc9 cells: Long-lived tumor-killing T cells for adoptive therapy
por: Lu, Yong, et al.
Publicado: (2014)

Regulatory T cells are redirected to kill glioblastoma by an EGFRvIII-targeted bispecific antibody
por: Choi, Bryan D, et al.
Publicado: (2013)

Inhibition of the mevalonate pathway to override chemoresistance and promote the immunogenic demise of cancer cells: Killing two birds with one stone
por: Riganti, Chiara, et al.
Publicado: (2013)

Killing two birds with one stone: Blocking the mitochondrial pyruvate carrier to inhibit lactate uptake by cancer cells and radiosensitize tumors
por: Linden, Catherine Vander, et al.
Publicado: (2018)

SAMHD1 Limits the Efficacy of Forodesine in Leukemia by Protecting Cells against the Cytotoxicity of dGTP
por: Davenne, Tamara, et al.
Publicado: (2020)

Smac mimetics combined with innate immune stimuli create the perfect cytokine storm to kill tumor cells
por: Beug, Shawn T, et al.
Publicado: (2014)

What does not kill you makes you stronger: surviving anti-cancer therapies by cytoskeletal remodeling and Myosin II reactivation
por: Orgaz, Jose L, et al.
Publicado: (2020)

Chemical parsing: Dissecting cell dependencies with a toolkit of selective BCL-2 family inhibitors
por: Leverson, Joel D.
Publicado: (2015)

Immunological consequences of selective BRAF inhibitors in malignant melanoma: Neutralization of myeloid-derived suppressor cells
por: Schilling, Bastian, et al.
Publicado: (2013)

The RIG-I/MAVS signaling pathway in cancer cell-selective apoptosis
por: Kaneda, Yasufumi
Publicado: (2013)

SAMHD1-dependent retroviral control and escape in mice
por: Rehwinkel, Jan, et al.
Publicado: (2013)

PD-L1 immune suppression in cancer: Tumor cells or host cells?
por: Kleinovink, Jan Willem, et al.
Publicado: (2017)

LSD1 inhibitors disrupt the GFI1 transcription repressor complex
por: Maiques-Diaz, Alba, et al.
Publicado: (2018)

Re-investigating PLK1 inhibitors as antimitotic agents
por: Delacour, Quentin, et al.
Publicado: (2017)

BRAF inhibitors in colorectal cancer: Toward a differentiation therapy?
por: Herr, Ricarda, et al.
Publicado: (2015)

HSP90 inhibitor antagonizing MIF: The specifics of pleiotropic cancer drug candidates
por: Schulz, Ramona, et al.
Publicado: (2012)

Targeting cancer stem cells with ALDH1A1-based immunotherapy
por: DeLeo, Albert B.
Publicado: (2012)

A mechanism for the response of KRAS(G13D) expressing colorectal cancers to EGFR inhibitors
por: McFall, Thomas, et al.
Publicado: (2020)

CX-5461 can destabilize replication forks in PARP inhibitor-resistant models of ovarian cancer
por: Xuan, Jiachen, et al.
Publicado: (2020)

The combination of histone deacetylase inhibitors with immune-stimulating antibodies has potent anti-cancer effects
por: West, Alison C., et al.
Publicado: (2012)

Potential utility of the pan-Bcl-2 inhibitor GX15–070 (obatoclax) in cancer immunotherapy
por: Kim, Peter S, et al.
Publicado: (2014)

Triple threat to cancer: rationale for combining oncolytic viruses, MEK inhibitors, and immune checkpoint blockade
por: Bommareddy, Praveen K., et al.
Publicado: (2019)

Inhibitors of cell cycle checkpoints and DNA replication cause different responses in normal versus malignant urothelial cells
por: Meuth, Mark
Publicado: (2014)

A dual role for SAMHD1 in regulating HBV cccDNA and RT-dependent particle genesis
por: Wing, Peter AC, et al.
Publicado: (2019)

Targeting ganglioneuromas with mTOR inhibitors
por: Tao, Ting, et al.
Publicado: (2021)

HDAC inhibitors and their potential applications to glioblastoma therapy
por: Adamopoulou, Eleni, et al.
Publicado: (2013)

Blockade of the PD-1 pathway enhances the efficacy of adoptive cell therapy against cancer
por: Peng, Weiyi, et al.
Publicado: (2013)

The anticancer effects of HDAC inhibitors require the immune system
por: West, Alison C, et al.
Publicado: (2014)

Restoration of tumor suppressor functions by small-molecule inhibitors
por: Pyndiah, Slovénie, et al.
Publicado: (2015)

Endosomal acidification inhibitors for the treatment of BRAF mutant tumors
por: Espinosa, Lluís
Publicado: (2015)

PARP1 inhibition elicits immune responses against non-small cell lung cancer
por: Juncheng, Pan, et al.
Publicado: (2022)

Synergistic antitumor effects of a TGFβ inhibitor and cyclophosphamide
por: Chen, Xin, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_s73ipe6s472do3tiq622e4t9um